SCHEMBL26062066

SCHEMBL26062066

CC(=O)C1(CCCCc2ccccc2CCCCC2(C(=O)O)CC2)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
MTNR1A P48039 2/20 0.34
MTNR1B P49286 1/20 0.34
ALDH1A1 P00352 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
BID P55957 4/20 0.33
MCL1 Q07820 4/20 0.33
BCL2L1 Q07817 3/20 0.33
BAK1 Q16611 3/20 0.33
KAT8 Q9H7Z6 2/20 0.33
PPARG P37231 2/20 0.33
PPARA Q07869 2/20 0.33
EP300 Q09472 1/20 0.33
KAT2A Q92830 1/20 0.33
KAT2B Q92831 1/20 0.33
KAT5 Q92993 1/20 0.33
SAE1 Q9UBE0 1/20 0.33
CETP P11597 1/20 0.33
CYSLTR2 Q9NS75 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26062073 0.98 BID (0.35) CYP4F2CYP4A11BIDMCL1BCL2L1
SCHEMBL26062074 0.98 BID (0.35) CYP4F2CYP4A11BIDMCL1BCL2L1
SCHEMBL26062077 0.98 BID (0.35) CYP4F2CYP4A11BIDMCL1BCL2L1
SCHEMBL25997257 0.98 BID (0.35) CYP4F2CYP4A11BIDMCL1BCL2L1
SCHEMBL25997249 0.98 BID (0.35) CYP4F2CYP4A11BIDMCL1BCL2L1
SCHEMBL25997246 0.98 BID (0.35) CYP4F2CYP4A11BIDMCL1BCL2L1
SCHEMBL25997236 0.95 ALDH1A1 (0.34) CYP4F2CYP4A11MTNR1AMTNR1BALDH1A1
SCHEMBL26062068 0.94 CYP4F2 (0.39) CYP4F2CYP4A11MTNR1AMTNR1BBID
SCHEMBL25997251 0.92 CYP4F2 (0.38) CYP4F2CYP4A11MTNR1ABIDMCL1
SCHEMBL25997261 0.92 CYP4F2 (0.38) CYP4F2CYP4A11MTNR1ABIDMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11737995-B2 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease ESPERVITA THERAPEUTICS, INC. (US) 2023-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11737995-B2 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease AHR, PKD1, CFTR CYP4F2 687/4885CYP4A11 605/4885MTNR1A 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.